Vor Biopharma Inc. (VOR)
NASDAQ: VOR
· Real-Time Price · USD
0.17
0.01 (6.25%)
At close: May 14, 2025, 3:59 PM
0.17
-0.70%
Pre-market: May 15, 2025, 04:43 AM EDT
Company Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients.
It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies.
The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.
The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers.
Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Vor Biopharma Inc.

Country | United States |
IPO Date | Feb 5, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 159 |
CEO | Dr. Robert Ang M.B.A., M.D., MBBS |
Contact Details
Address: 100 Cambridgepark Drive Cambridge, Massachusetts United States | |
Website | https://www.vorbio.com |
Stock Details
Ticker Symbol | VOR |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001817229 |
CUSIP Number | 929033108 |
ISIN Number | US9290331084 |
Employer ID | 00-0000000 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Robert Ang M.B.A., M.D., MBBS | President, Chief Executive Officer & Director |
Dr. Han Choi M.D. | Chief Financial Officer |
Tania Philipp | Chief People Officer |
Amy Quinlan | Interim Principal Accounting Officer |
David Phillips M.B.A. | Senior Vice President & Head of Quality |
Dr. Tirtha Chakraborty Ph.D. | Chief Scientific Officer & Head of Technical Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 14, 2025 | 10-Q | Quarterly Report |
May 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
May 08, 2025 | 8-K | Current Report |
May 07, 2025 | 4 | Filing |
May 07, 2025 | 4 | Filing |
May 02, 2025 | 4 | Filing |
May 02, 2025 | 4 | Filing |
May 02, 2025 | 4 | Filing |
Apr 30, 2025 | DEFR14A | Filing |
Apr 25, 2025 | 8-K | Current Report |